Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tel Aviv University
The study examines giving depressive participants gaze-contingent feedback as a novel attention training procedure. Half of the participants will receive contingent feedback while the other half would receive non-contingent "placebo" feedback.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A signed consent form
Men and women between the ages of 18 and 65.
Meeting a current diagnosis of Major Depressive Disorder (MDD) according to the DSM-IV
MDD as the primary diagnosis: In cases of co-morbidity, MDD will be deemed as the most distressing and clinically significant condition among the co-morbid disorders
Stable pharmaco-therapy: Participants receiving a pharmacological treatment who are taking a stable medication for at least 3 months before the beginning of the procedure.
You may not be if
Psychotic episode in the past or the present time.
Co-morbidity with any neurological disorder (i.e., epilepsy, brain injury).
Another psychotherapeutic treatment during the study.
Usage of neuroleptic medication.
Change in medication status during the study.
Substantial usage of drugs or alcohol in the present time.
Poor judgment capacity (i.e., children under 18 and special populations).
High Risk of Suicide.
Clareo Health | Gaze Contingent Feedback in Major Depressive Disorder (MDD)
